Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirty-one ratings firms that are covering the firm, ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...

That's what recently happened to Vertex Pharmaceuticals (NASDAQ: VRTX), a biotech company. Here is why now is as good a time as any to "buy low" when it comes to this stock. Vertex Pharmaceuticals ...

In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...

Vertex Pharmaceuticals (VRTX ... Elsewhere, the Dow gained 0.91%, while the tech-heavy Nasdaq added 1.35%. The the stock of drugmaker has fallen by 12.22% in the past month, lagging the Medical ...

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price objective trimmed by Barclays from $509.00 to $418.00 in a ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global ...